Continual Reassessment Method for Ordered Groups
From MaRDI portal
Publication:3079132
DOI10.1111/1541-0420.00050zbMath1210.62198OpenAlexW2054512290WikidataQ48583772 ScholiaQ48583772MaRDI QIDQ3079132
Xavier Paoletti, John O'Quigley
Publication date: 1 March 2011
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/1541-0420.00050
clinical trialsordered groupsdose-finding studiesmaximum tolerated dosetwo-sample problemcontinual reassessment methodtoxicitypharmacologyphase I designs
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Medical applications (general) (92C50)
Related Items (14)
Patient-specific dose finding in phase I clinical trials ⋮ A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes ⋮ Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates ⋮ Continual reassessment and related dose-finding designs ⋮ Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity ⋮ Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate ⋮ Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates ⋮ Two‐Dimensional Dose Finding in Discrete Dose Space ⋮ Risk-Group-Specific Dose Finding Based on an Average Toxicity Score ⋮ Theoretical study of the continual reassessment method ⋮ A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents ⋮ Individualized dosing for multiple ordered groups of patients
Cites Work
This page was built for publication: Continual Reassessment Method for Ordered Groups
